<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T18:08:22Z</responseDate>
  <request identifier="oai:figshare.com:article/33809656" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33809656</identifier>
        <datestamp>2026-09-15T17:24:56Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_15</setSpec>
        <setSpec>category_16</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Nicotinic acetylcholine receptor occupancy within neuromuscular junction area across exposure groups.&lt;/p&gt;</dc:title>
          <dc:creator>Kaitlyn M. Miller (18831310)</dc:creator>
          <dc:creator>Dakota R. McMeans (24680662)</dc:creator>
          <dc:creator>Martha J. Sonner (3697321)</dc:creator>
          <dc:creator>David R. Ladle (3697324)</dc:creator>
          <dc:creator>Shannon H. Romer (14297822)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>Physiology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>would provide neuroprotection</dc:subject>
          <dc:subject>various pathological effects</dc:subject>
          <dc:subject>plasma cholinesterase activity</dc:subject>
          <dc:subject>field motor activity</dc:subject>
          <dc:subject>causes adverse effects</dc:subject>
          <dc:subject>functional deficits corresponded</dc:subject>
          <dc:subject>galantamine treatment protected</dc:subject>
          <dc:subject>hindlimb nmj innervation</dc:subject>
          <dc:subject>health effects associated</dc:subject>
          <dc:subject>like repeated exposure</dc:subject>
          <dc:subject>week recovery period</dc:subject>
          <dc:subject>kg ), galantamine</dc:subject>
          <dc:subject>like malathion exposure</dc:subject>
          <dc:subject>concentration malathion exposure</dc:subject>
          <dc:subject>reversible ache inhibitor</dc:subject>
          <dc:subject>kg ),</dc:subject>
          <dc:subject>reversible acetylcholinesterase</dc:subject>
          <dc:subject>locomotor deficits</dc:subject>
          <dc:subject>repeated low</dc:subject>
          <dc:subject>final exposure</dc:subject>
          <dc:subject>acute exposure</dc:subject>
          <dc:subject>synaptic remodeling</dc:subject>
          <dc:subject>suggesting remodeling</dc:subject>
          <dc:subject>spinal mns</dc:subject>
          <dc:subject>spinal astrogliosis</dc:subject>
          <dc:subject>performance changes</dc:subject>
          <dc:subject>nmjs consistent</dc:subject>
          <dc:subject>neuromuscular junction</dc:subject>
          <dc:subject>neuromuscular alterations</dc:subject>
          <dc:subject>less understood</dc:subject>
          <dc:subject>indicating involvement</dc:subject>
          <dc:subject>evaluated immediately</dc:subject>
          <dc:subject>anatomical alterations</dc:subject>
          <dc:subject>adult male</dc:subject>
          <dc:subject>50 mg</dc:subject>
          <dc:subject>0 mg</dc:subject>
          <dc:description>&lt;p&gt;Nicotinic acetylcholine receptor occupancy within neuromuscular junction area across exposure groups.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-15T17:24:33Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pone.0357900.t006</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Nicotinic_acetylcholine_receptor_occupancy_within_neuromuscular_junction_area_across_exposure_groups_p_/33809656</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
